Abstract Number: 2212 • 2018 ACR/ARHP Annual Meeting
Feasibility and Performance of HR-pQCT-Derived Joint Space Width Measurement As Outcome Parameter in Arthropathic Disease – Lessons from Hemochromatosis Arthropathy
Background/Purpose: High resolution peripheral quantitative computed tomography (HR-pQCT) allows in vivo 3 D imaging of human joint microstructure and joint space width (JSW) at an…Abstract Number: 2213 • 2018 ACR/ARHP Annual Meeting
Usefulness of Shoulder Radiographs to Aid in Determining Need for Advanced Imaging to Detect Operable or Inoperable Full-Thickness Rotator Cuff Tears
Background/Purpose: Full-thickness rotator cuff tears (FTT) can be a debilitating cause of shoulder pain and loss of function. Delay in surgical evaluation may result in…Abstract Number: 2214 • 2018 ACR/ARHP Annual Meeting
Lung Involvement in Primary Sjögren’s Syndrome: Spectrum of Pulmonary Abnormalities and Computed Tomography Findings
Background/Purpose: Primary Sjögren's syndrome (pSS) is a chronic autoimmune disease that affects exocrine glands. It can generate pulmonary compromise due to dysfunction of the glandular…Abstract Number: 2215 • 2018 ACR/ARHP Annual Meeting
Evaluation of Left Ventricular Systolic and Diastolic Myocardial Function in Patients with Ankylosing Spondylitis By Speckle-Tracking Echocardiography
Background/Purpose: Patients with ankylosing spondylitis (AS) are at increased risk for cardiovascular disease (CVD), although strategies to detect subclinical CVD are poorly characterized. The aim…Abstract Number: 2216 • 2018 ACR/ARHP Annual Meeting
Detection of Left Ventricular Regional Function in Primary Sjögren’s Syndrome Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging
Background/Purpose: The risk of major cardiovascular (CV) events and the long-term CV outcome in patients with primary Sjögren’s syndrome (pSS) remain unclear. Myocardial disease is…Abstract Number: 2217 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Early Onset Gout in Outpatient Setting
Background/Purpose: There has been an increase in the prevalence of gout over the past two decades, with increasing number of patients presenting at younger age.…Abstract Number: 2218 • 2018 ACR/ARHP Annual Meeting
Use of Anakinra in Hospitalized Patients with Acute Crystalline Arthritis
Background/Purpose: Medically complex individuals may have contraindications to standard therapies for acute arthritis secondary to gout or calcium pyrophosphate disease (CPPD). Observational studies have demonstrated…Abstract Number: 2219 • 2018 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers
Background/Purpose: Gout flare due to rapid urate reduction after initiating urate-lowering therapy (ULT) is one of the major issues in the therapy. International guidelines recommend…Abstract Number: 2220 • 2018 ACR/ARHP Annual Meeting
Gout, Flares and Allopurinol Use: A Population Based Study
Background/Purpose: Gout flares may often be self-managed, but there is a paucity of population-based data. The aim of this study was to determine the prevalence…Abstract Number: 2221 • 2018 ACR/ARHP Annual Meeting
Systematic Genetic Analysis of Early-Onset Gout: ABCG2 141K Is the Strongest Predictor
Background/Purpose: Although increasing age is an important risk factor for development of gout, disease can develop in younger people. The aim of this study was…Abstract Number: 2222 • 2018 ACR/ARHP Annual Meeting
Construct Validity of Provisional Remission Criteria for Gout: A Dual Energy CT Study
Background/Purpose: Provisional domains and definitions for gout remission criteria have been proposed using consensus methodology (de Lautour et al, Arthritis Care Res 2016). These criteria…Abstract Number: 2223 • 2018 ACR/ARHP Annual Meeting
Proton Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition (CPPD) in a Population-Based Study
Background/Purpose: There are no therapies available that specifically target CPPD, with treatment limited to symptomatic management. Hypomagnesemia is a recognized risk factor for CPPD, and…Abstract Number: 2224 • 2018 ACR/ARHP Annual Meeting
Interactions between Serum Urate-Associated Genetic Variants and Sex on Gout Risk in a European Population
Background/Purpose: Sex-specific differences in the effect size of genetic variants on serum urate levels have been described, with SLC2A9 variants having a greater influence on…Abstract Number: 2225 • 2018 ACR/ARHP Annual Meeting
Exploring the Relationship between Gout and Diffuse Idiopathic Skeletal Hyperostosis (DISH): An Epidemiologic and Genetic Study
Background/Purpose: Gout has been reported to be a risk factor for development of diffuse idiopathic skeletal hyperostosis (DISH), a condition characterized by abnormal bone formation…Abstract Number: 2226 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study
Background/Purpose: The pursuit of a link between gout/hyperuricemia and dementia has led to contradictory results. Most observational studies, including population-based studies, showed that hyperuricemia was…